# Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection

> **NCT06276504** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 33 (estimated)

## Conditions studied

- Progressive Multifocal Leukoencephalopathy

## Interventions

- **DRUG:** Pembrolizumab, 25 mg/ml solution for intravenous (IV) injection

## Key facts

- **NCT ID:** NCT06276504
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-04
- **Primary completion:** 2028-04
- **Final completion:** 2028-04
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2024-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06276504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06276504, "Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06276504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*